Cointime

Versameb

company

About

Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.

Highlights

Total Funding Amount
Fr17.70M
Funding Rounds
3
Investors
1
Employee Profiles
7

Details

Last Funding Type
Seed
Last Funding Money Raised
Fr6M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Versameb AG

Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team.
The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in multiple disease areas with high unmet medical need.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
Fr17.70M
Versameb has raised a total of Fr17.70M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2020 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 15, 2020 Seed Fr6M — — — Detail
Oct 17, 2019 Seed Fr6.40M — — — Detail
Dec 27, 2018 Seed Fr5.30M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Versameb is funded by 1 investors. Penny Schiffer are the most recent investors.
Investor Name Lead Investor Funding Round
Penny Schiffer — Seed

Employee Profiles

Number of Employee Profiles
7
Versameb has 7 current employee profiles, including Board member Reinhard Ambros
Reinhard Ambros
Board member
Urs Breitenstein
Executive
Roger Meier
Executive
Friedrich Metzger
Executive
Tatsuo Satoh
Executive
Show More
Cointime
İçerikler
Şirket.